Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Allison Berger"'
Autor:
Evan F. Lind, Vi Lam, Nathan D. Pennock, Scott R Best, Adam Kittai, Alexey V. Danilov, Nur Bruss, Allison Berger, Susan E. Murray, Tingting Liu, Olga V. Danilova
Publikováno v:
Leukemia
Novel targeted agents used in therapy of lymphoid malignancies, such as inhibitors of B-cell receptor-associated kinases, are recognized to have complex immune-mediated effects. NEDD8-activating enzyme (NAE) has been identified as a tractable target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcae410fe576a9e2b7a646012b4569dc
https://europepmc.org/articles/PMC8288064/
https://europepmc.org/articles/PMC8288064/
Autor:
Neil MacLean, Shawn Brennan, Adam C. Smith, Rose Hurren, Allison Berger, Xiaoming Wang, Razq Hakem, Marcela Gronda, Mark D. Minden, Sara Farshchi Zarabi, Simon Kavanagh, Tary Traore, G. Wei Xu, Aaron D. Schimmer, Emil F. Pai, Samir H. Barghout, Ondrej Halgas, Michael Milhollen, Marc L. Hyer, Parasvi S. Patel, Danny V. Jeyaraju
Publikováno v:
Leukemia. 33:37-51
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme
Autor:
J. Claire Godbersen, Christopher George Danes, Taylor Rowland, Alexey V. Danilov, Cody Paiva, Allison Berger, Olga V. Danilova
Publikováno v:
Oncotarget
// Cody Paiva 1, * , J. Claire Godbersen 2, * , Taylor Rowland 1 , Olga V. Danilova 3 , Christopher Danes 4 , Allison Berger 4 , Alexey V. Danilov 1 1 Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA 2 Geisel School of
Autor:
Todd M. Pitts, Alice McDonald, John J. Tentler, Aik Choon Tan, Kit Man Wong, Peter G Smith, Peter J. Klauck, Stacey M. Bagby, S. Gail Eckhardt, Anna Spreafico, Heather M. Selby, Stephen J. Blakemore, Allison Berger, Lindsey N. Micel
Publikováno v:
Investigational New Drugs. 35:11-25
Background The neddylation pathway conjugates NEDD8 to cullin-RING ligases and controls the proteasomal degradation of specific proteins involved in essential cell processes. Pevonedistat (MLN4924) is a selective small molecule targeting the NEDD8-ac
Autor:
Craig Okada, Alexey V. Danilov, Nur Bruss, Allison Berger, Cody Paiva, Tingting Liu, Adam Kittai, Scott R Best, Taylor Hashiguchi
Publikováno v:
Blood advances. 3(1)
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin lymphoma (NHL), no
Autor:
Glen J. Weiss, John S. Kauh, Bruce J. Dezube, Jeffrey W. Clark, Roger B. Cohen, Devalingam Mahalingam, James M. Cleary, Hélène M. Faessel, Allison Berger, Michael D. Pickard, George Mulligan, Kristin E. Burke, R. Donald Harvey, Geoffrey I. Shapiro, John Sarantopoulos
Publikováno v:
Clinical Cancer Research. 22:847-857
Purpose: To determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) and to investigate pevonedistat pharmacokinetics and pharmacodyna
Autor:
Fazal Shirazi, Marc L. Hyer, R. Eric Davis, Isere Kuiatse, Hans C. Lee, Vaishali Shinde, Allison Berger, Hua Wang, Junling Zhuang, Sakeena Syed, Zhiqiang Wang, Zuzana Berkova, Robert Z. Orlowski, Richard J. Jones, Nibedita Chattopadhyay, Judy Qiuju Shi, Jie Yu, Stephen Tirrell, Ram Kumar Singh
Publikováno v:
Blood. 133(14)
Three proteasome inhibitors have garnered regulatory approvals in various multiple myeloma settings; but drug resistance is an emerging challenge, prompting interest in blocking upstream components of the ubiquitin-proteasome pathway. One such attrac
Autor:
Yiguo Hu, Samir B. Amin, Dharminder Chauhan, Yu-Tzu Tai, Ze Tian, Allison Berger, Paul G. Richardson, Kenneth C. Anderson, Jianjun Zhao
Publikováno v:
Blood. 120:3958-3967
miRs play a critical role in tumor pathogenesis as either oncogenes or tumor-suppressor genes. However, the role of miRs and their regulation in response to proteasome inhibitors in multiple myeloma (MM) is unclear. In the current study, miR profilin
Autor:
Mitchell R. Smith, Catherine Diefenbach, Kevin R. Kelly, Andrzej Jakubowiak, Zhaowei Hua, R. Donald Harvey, Sagar Lonial, Daniel Lebovic, Bruce J. Dezube, George Mulligan, Hélène M. Faessel, Owen A. O'Connor, Jatin J. Shah, Stephen Tirrell, Robert Z. Orlowski, Allison Berger
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(1)
Purpose: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory l
Autor:
Jill Donelan, Stephen Tirrell, Erik Koenig, Bradley Stringer, Kristen Jordan, Cindy Q. Xia, Mark Manfredi, Allison Berger, Yu Yang, Angel Maldonado Lopez, James Garnsey, Nelson Rhodes, Katherine Galvin, Ben Amidon, Paul Hales, Nibedita Chattopadhyay, Hugues Bernard, Bret Bannerman, Greg Hather
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144825 (2015)
PLoS ONE
PLoS ONE
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to